Patents Assigned to Moexa Pharmaceuticals Limited
  • SMAD3 inhibitors
    Patent number: 12090149
    Abstract: Smad3 inhibitor compounds, specifically a compound of Formula 1 or Formula 2, or a pharmaceutically acceptable salt thereof, and its use in treating or preventing cell proliferation or cancer in a subject are provided.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: September 17, 2024
    Assignee: Moexa Pharmaceuticals Limited
    Inventor: Ho Yin Lo